Retrospective Study
Copyright ©The Author(s) 2025.
World J Clin Oncol. Jun 24, 2025; 16(6): 106228
Published online Jun 24, 2025. doi: 10.5306/wjco.v16.i6.106228
Figure 3
Figure 3 Survival curves of patients with swollen lymph node metastasis. Patients who received neoadjuvant chemotherapy had a significantly higher overall survival (OS) rate (5-year OS: 20.2% vs 9.3%, P = 0.029) and longer median survival time (18.0 months vs 14.0 months, P = 0.029) than those who did not.